Beta-cell rest: a strategy for the prevention of autoimmune diabetes.
An autoantigen being recognized by specific receptors is the key reaction of an autoimmune disease. Whereas much efforts have been made to develop immunosuppressive regimens which reduce the amount of effector cells, and/or inhibit receptor activation, surprisingly little attention has been paid to reduce the ligand-receptor interaction by interfering with the amount of antigen being presented from the target cells. In this review, we discuss clinical observations in autoimmune endocrine disease which illustrate that target cell alterations can modify the disease activity and comment on recent clinical trials which indicate that beta-cell rest may be beneficial to the course of human autoimmune diabetes mellitus.
Karlsson
F A
FA
Department of Medicine, University Hospital, Uppsala, Sweden.
Björk
E
E
D001323:Autoantibodies / Q000096:biosynthesis / Q000276:immunology; D001324:Autoantigens / Q000096:biosynthesis / Q000276:immunology; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000517:prevention & control*; D003981:Diazoxide / Q000494:pharmacology / Q000627:therapeutic use; D018450:Disease Progression; D005786:Gene Expression Regulation; D006801:Humans; D007328:Insulin / Q000096:biosynthesis; D007329:Insulin Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D007515:Islets of Langerhans / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D012075:Remission, Spontaneous
D001323:Autoantibodies; D001324:Autoantigens; D007328:Insulin; D007329:Insulin Antagonists; D003981:Diazoxide